The 54-year-old teamed up with the nonprofit organization “Power to the Patients” to push politicians to prioritize healthcare price transparency in the upcoming election that’s just over 30 ...

A student runs the website Cuiiliste.de together with friends. His aim is to ensure greater transparency for domains blocked under copyright law. A student who calls himself Damian also took up ...

This innovative door allows users to toggle between transparent and opaque modes with just the flip of a switch or a voice command. The door's standout feature is its electric smart glass window ...

Oct 4 (Reuters) - Italian pharma group Recordati (RECI.MI), opens new tab said on Friday it would buy from Sanofi (SASY.PA), opens new tab the global rights to a drug used to treat cold agglutinin ...

Recordati has reached an agreement with Sanofi for acquiring the worldwide rights to Enjaymo, the only approved treatment specifically targeting cold agglutinin disease (CAD), a rare B-cell ...

(Reuters) -Italian pharma group Recordati said on Friday it would buy from Sanofi the global rights to a drug used to treat cold agglutinin disease (CAD), a rare autoimmune disorder, for $825 ...

Milan, 4 th October 2024 – Recordati today announces an agreement with Sanofi to acquire the global rights to Enjaymo® (sutimlimab), a biologic which is the only approved targeted product for ...

Recordati SpA is shelling out $825 million up front for global rights to Enjaymo (sutimlimab), the only therapy approved for treating the rare disease cold agglutinin disease. In the deal with Sanofi ...

(Reuters) -Italian pharma group Recordati said on Friday it would buy from Sanofi the global rights to a drug used to treat cold agglutinin disease (CAD), a rare autoimmune disorder, for $825 million, ...

Subject to the closing date, Recordati expects minimal revenue contribution in 2024. The transaction is expected to be immediately accretive at the EBITDA level, with margin above the current Rare ...

Recordati reached an agreement with French pharmaceutical company Sanofi to acquire the global rights to autoimmune disorder treatment Enjaymo for $825 million. The Italian pharmaceutical company ...